Hong Kong Software Stock News

SEHK:6990
SEHK:6990Biotechs

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500. The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s...
SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Weakness

Everest Medicines Stock Moves After Recent Performance Metrics Everest Medicines (SEHK:1952) has drawn fresh attention as investors review recent share performance and financial metrics, with the stock down 1% over the past day and 4.6% over the past week. See our latest analysis for Everest Medicines. That 1 day and 7 day share price weakness comes on top of a 30 day share price return of down 14.8% and a year to date decline of 24.1%. The 3 year total shareholder return of about 1.7x the...
SEHK:1211
SEHK:1211Auto

BYD Takes On Driver Risk While Advancing Toward Solid State Batteries

BYD (SEHK:1211) has said it will assume liability for its advanced driver-assistance system, signaling a higher level of accountability for its technology. The company has also outlined plans to introduce solid-state batteries by 2027, targeting the next generation of electric vehicle battery performance. BYD shares last closed at HK$89.7, with the stock down 32.5% over the past year and still positive over 3 and 5 years, up 10.5% and 29.5% respectively. Against that backdrop, the company...
SEHK:1919
SEHK:1919Shipping

Assessing COSCO SHIPPING Holdings (SEHK:1919) Valuation After Dividend Approval And Leadership Changes

Leadership and dividend moves reshaping the picture for COSCO SHIPPING Holdings COSCO SHIPPING Holdings (SEHK:1919) has just combined a fresh round of leadership appointments with approval of its 2025 final dividend, a pairing that gives investors new information on both governance and cash returns. See our latest analysis for COSCO SHIPPING Holdings. The share price reaction has been strong around these announcements, with a 1-day share price return of 6.68% and a 7-day share price return of...
SEHK:9999
SEHK:9999Entertainment

Assessing NetEase (SEHK:9999) Valuation After Recent Share Price Weakness And Ongoing Global Expansion

Recent share performance and business snapshot NetEase (SEHK:9999) has drawn investor attention after recent share price moves, with the stock down 2.3% on the day and 1 day weakness extending through the past week. Over the past month the stock is up 3.8%, while performance over the past 3 months is roughly flat, showing a 0.4% decline. Year to date, the share price is down 17.7%, and the 1 year total return shows a 3% decline. Over longer periods, NetEase has delivered a 39.1% total return...
SEHK:2269
SEHK:2269Life Sciences

Is WuXi Biologics (SEHK:2269) Offering Value After Its Recent Share Price Recovery?

If you are wondering whether WuXi Biologics (Cayman) is attractively priced or still carrying past baggage, the key is to separate headline moves from underlying value. The stock last closed at HK$32.74, with returns of 0.6% year to date and 32.8% over the past year, even though it is still down 27.0% over three years and 73.8% over five years. Recent share price moves have come alongside ongoing attention on WuXi Biologics (Cayman)'s role in global biologics development and contract...
SEHK:2696
SEHK:2696Biotechs

Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, completing a China, US and EU approval set. See our latest analysis for Shanghai Henlius Biotech. Despite the HANBEIYOU catalyst and a string of recent trial starts in oncology and immunology, Shanghai Henlius Biotech’s share price has been under pressure in the near term, with the 7 day and 30...
SEHK:113
SEHK:113Specialty Retail

Improved 12.5% Margin At Dickson Concepts (SEHK:113) Tests Longer Term Bearish Earnings Narrative

Dickson Concepts (International) (SEHK:113) has put up solid headline numbers for FY 2026 so far, with first half revenue of HK$973.4 million and basic EPS of HK$0.39. Net profit margin over the last 12 months has improved to 12.5% from 10.3% a year earlier as earnings grew 25.7%. Over recent periods the company has seen revenue move from HK$961.8 million in 1H FY 2025 to HK$959.9 million in 2H FY 2025 and then to HK$973.4 million in 1H FY 2026. Basic EPS has also stepped through HK$0.33,...